Skip to content

Animal-Assisted Therapy in the Residential Treatment of Schizophrenia and Addictions

Animal-Assisted Therapy in the Residential Treatment of Schizophrenia and Addictions

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05103865
Enrollment
160
Registered
2021-11-02
Start date
2015-11-03
Completion date
2019-09-10
Last updated
2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diagnosis, Dual (Psychiatry)

Keywords

Animal-assisted therapy, everyday life skills, schizophrenia, residential treatment, dual pathology

Brief summary

Animal-assisted therapy (AAT) is a complementary intervention of therapy that has shown positive results in the treatment of various pathologies. This study assesses the viability of the implementation and the efectiveness of an AAT program in patients diagnosed with substance abuse disorder and associated mental disorders (dual pathology).

Detailed description

Animal assisted therapy (AAT) is a complementary intervention to therapy that presents positive results in the treatment of different pathologies. The study assesses the implementation and effectiveness of a TAA program in patients diagnosed with substance use disorder and schizophrenia spectrum disorder.

Interventions

BEHAVIORALAnimal-assisted therapy (AAT)
OTHERusual treatment

Sponsors

Miguel Monfort Montolio
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Meeting DSM-5 criteria for substance abuse disorder and the presence of schizophrenia * Voluntary participant in the study and having signed the informed consent

Exclusion criteria

* Patients whose functioning could be altered by factors not specifically related to addictive pathology or mental disorder (severe cognitive impairment, intellectual deficiency or language barrier) * Animal-specific phobia

Design outcomes

Primary

MeasureTime frameDescription
The Life Skills Profile questionnaire (LSP)Change from Life Skills at 3-6-9 months (12 minutes)This questionnaire evaluates aspects of functioning that affect daily activities and the adaptation of people with mental illnesses in the community. It contains 39 items that are grouped into self-care, social-interpersonal behaviour, communication-social contact, non-personal social behaviour and autonomous life
Barrat impulsiveness scale (BIS-11)Change from impulsiveness at 3-6-9 months (12 minutes)This instrument is composed of 30 items distributed into three sub-scales: nonplanning, motor and attentional. The total impulsiveness score was also obtained.
Calgary Depresión Scale for Schizophrenia (CDSS)Change from Depresión at 3-6-9 months (12 minutes)El cuestionario es un intrumento estructurado, adminisitrado por un clínico de forma heteroaplicada para población adulta, con un tiempo aproximado de administración de entre 10 y 30 minutos, y aborada el área terapéutica relativa a la sintomatología de los trastornos depresivos.
Rosenberg Self-Esteem ScaleChange from self.-esteem at 3-6-9 months (12 minutes)The questionnaire consists of 10 statements of the feelings that the person has about himself. Five of the statements are addressed positively (items 1, 2, 4, 6 and 7) and 5 negatively (items 3, 5, 8, 9 and 10).
Positive and negative symptom scale (PANSS)Change from Positive and negative symptom at 3-6-9 months (12 minutes)It is a semi-structured and hetero-applied questionnaire for the adult population. The application time is between 30-60 minutes and evaluates the positive and negative symptoms of schizophrenia and other psychotic disorders.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026